Want to see HK:6086 full AI Analyst Report?
6086 Stock Chart & Stats
HK$3.63
HK$0.21(4.98%)
At close: 4:00 PM EST
HK$3.63
HK$0.21(4.98%)
Day’s Range― - ―
52-Week RangeHK$0.63 - HK$4.40
Previous CloseN/A
Volume737.00K
Average Volume (3M)307.62K
Market Cap
HK$1.05B
Enterprise ValueHK$376.38
Total Cash (Recent Filing)HK$505.18M
Total Debt (Recent Filing)HK$22.88M
Price to Earnings (P/E)111.9
Beta1.59
Next Earnings
Mar 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,385,448,500
10 Day Avg. Volume210,900
30 Day Avg. Volume307,616
Financial Highlights & Ratios
PEG Ratio-2.25
Price to Book (P/B)17.52
Price to Sales (P/S)0.76
P/FCF Ratio41.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.00Price Target Upside65.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$4.47B
Bulls Say, Bears Say
Bulls Say
Revenue And Earnings TurnaroundRevenue growth of about 19% alongside a return to positive operating profit and net income indicates that the business improved materially in 2025. If sustained, this turnaround can broaden operating scale and provide a stronger base for investment and earnings generation over the next several quarters.
Positive Cash GenerationPositive operating cash flow and free cash flow indicate improved earnings quality and working-capital performance compared with prior years. This gives Fangzhou greater internal funding capacity and can reduce reliance on external financing if cash generation remains positive over the coming quarters.
Improved LeverageLower debt-to-equity and positive equity in 2025 point to improved financial stability and greater resilience than in the prior year. A healthier balance sheet can preserve flexibility for operations and reduce the immediate pressure that debt places on cash allocation.
Bears Say
Very Thin ProfitabilityProfitability remains exceptionally thin despite the earnings turnaround, while declining gross margin suggests limited pricing power and or higher costs. Such a narrow earnings buffer leaves less room to absorb operating setbacks and makes durable net-income growth harder to establish.
Historical Losses And Balance-Sheet VolatilitySizable recent losses and periods of negative equity show that financial stability has not yet been proven across cycles. Although 2025 improved, another earnings setback could create balance-sheet strain, governance or structural concerns, and pressure for recapitalization.
Inconsistent Cash GenerationThe return to positive free cash flow is encouraging, but sharp year-over-year deterioration in its growth and inconsistency across periods indicate that cash generation may not yet be firmly established. This can weaken funding reliability and complicate longer-term capital planning.
Fangzhou Inc. News
6086 FAQ
What was Fangzhou Inc.’s price range in the past 12 months?
Fangzhou Inc. lowest stock price was HK$0.63 and its highest was HK$4.40 in the past 12 months.
What is Fangzhou Inc.’s market cap?
Fangzhou Inc.’s market cap is HK$1.05B.
When is Fangzhou Inc.’s upcoming earnings report date?
Fangzhou Inc.’s upcoming earnings report date is Mar 19, 2027 which is in 173 days.
How were Fangzhou Inc.’s earnings last quarter?
Fangzhou Inc. released its earnings results on Aug 27, 2026. The company reported HK$0.012 earnings per share for the quarter.
Is Fangzhou Inc. overvalued?
According to Wall Street analysts Fangzhou Inc.’s price is currently Undervalued.
Does Fangzhou Inc. pay dividends?
Fangzhou Inc. does not currently pay dividends.
What is Fangzhou Inc.’s EPS estimate?
Fangzhou Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fangzhou Inc. have?
Fangzhou Inc. has 1,385,448,500 shares outstanding.
What happened to Fangzhou Inc.’s price movement after its last earnings report?
Fangzhou Inc. reported an EPS of HK$0.012 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Fangzhou Inc.?
Currently, no hedge funds are holding shares in HK:6086
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fangzhou Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
33.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Fangzhou Inc.
Headquartered in Guangzhou, China, Fangzhou Inc. delivers comprehensive online chronic disease management services throughout the nation. The company leverages its dedicated digital platform to assist individuals grappling with long-term health issues like hypertension, cardiovascular, and respiratory conditions. Its mobile application facilitates a suite of "H2H" services, comprising virtual medical consultations, e-prescribing, and prescription renewal options. Furthermore, Fangzhou provides healthcare products through an online retail pharmacy and manages its own network of hospitals and brick-and-mortar pharmacies. The company was established in 2015.
6086 Stock 12 Month Forecast
Average Price Target
HK$6.00
▲(65.29% Upside)
Technical Analysis
Dingdang Health Technology Group Ltd.
―
CANbridge Pharmaceuticals Inc.
―
Modern Chinese Medicine Group Co. Ltd.
―
Sunho Biologics,Inc.
―
Beijing Biostar Pharmaceuticals Co., Ltd. Class H
―